Efficacy and safety of hepatic arterial infusion of XXXX with @entity4181 as salvage treatment for refractory liver metastases from @entity14 .

@entity1 @entity4181 @entity137 @entity3136 @entity281 @entity14 @entity490 @entity715 @entity1487
BACKGROUND/AIMS: Limited options remain for @entity1 with metastatic @entity14 ( @entity14 ) after failure of standard systemic chemotherapy. Readministration of chemotherapeutic agents by hepatic arterial infusion (HAI) has the rationale of providing higher concentrations of chemotherapeutic agents to hepatic metastases. The present study was conducted to evaluate the efficacy and safety of HAI of @entity1487 with @entity4181 (HAI 5-FU/LV) for @entity1 with liver metastases from @entity14 . METHODS: Fourteen @entity1 with liver metastases from @entity14 who received HAI 5-FU/LV after failure of systemic chemotherapy containing @entity1487 and @entity4181 were identified and their medical records were reviewed. RESULTS: Of 10 @entity1 evaluable for response, one partial response, six stable disease, and three progressive disease were reported. Additionally, the overall response and disease control rates were 7% and 50%, respectively. The median time to progression was 4.3 months (range, 2.9 to 5.6), to hepatic progression was 5.8 months (range, 4.7 to 6.9), and to extrahepatic progression was 5.8 months (range, 2.3 to 9.2). No grade 3/4 hematologic @entity137 occurred and one case of @entity490 and two cases of @entity3136 were the only grade 3 nonhematologic @entity137 . Catheter-related complications occurred in three @entity1 : one @entity715 , one @entity281 , and one displacement. CONCLUSIONS: HAI 5-FU/LV was well tolerated and showed modest efficacy for @entity1 with liver metastases from refractory @entity14 . Readministration of previously used chemotherapeutic agents via the hepatic artery could be an effective salvage option and warrants further investigation in a prospective trial.
